Life-time cost of averted HIV infection for simplified cost-effectiveness analysis of preventative interventions

Barinova A. N.
Federal State Budgetary Educational Institution for Higher Training «North-Western State Medical University named after I.I. Mechnikov» Ministry of Health of the Russian Federation, 191015, Sankt-Petersburg, Russia

Plavinskii S. L.
Federal State Budgetary Educational Institution for Higher Training «North-Western State Medical University named after I.I. Mechnikov» Ministry of Health of the Russian Federation, 191015, Sankt-Petersburg, Russia

Implementation of a preventive programs directed at the HIV infection spread demands evaluation of its effectiveness judged by the number of HIV cases averted taking into account cost incurred. To simplify comparison of interventions in HIV filed and other medical fields a simplified cost-effectiveness analysis was proposed which is based on cost of HIV case completed with estimation of quality-adjusted life years (QALY) lost due to infection. Using model of HIV progression it was showed that cost of one HIV case is 1720 thousand rubles for males and 2195 thousand rubles for females (annual discount rate is 3.5%) taking present cost of antiretroviral therapy. One HIV case even if HIV treatment is optimal is associated with loss of 6,4 QALY in males and 4,4 QALY in females. Use of simplified cost-effectiveness analysis for comprehensive HIV prevention programs for intravenous drug users demonstrated that those programs incurred costs off by cutting down future treatment costs.

HIV-infection, cost-effectiveness, QALY, injecting drug users, prevention, public health

1. Aleksandrova, G. A., G. S. Lebedev, and E. V. Ogryzko. Socially Significant Diseases of Russia's Population in 2013. Moscow: Department of Monitoring, Analysis and Strategic Health Development; Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation, 2014.

2. Pokrovskij, V. V., and N. N. Ladnaya. HIV Infection. Newsletter. Vol. 40. Moscow: Federal Scientific and Methodological Center for Prevention and Control of AIDS, 2015.

3. Pinkerton, S. D., and D. R. Holtgrave. Assessing the Cost-Effectiveness of HIV Prevention Interventions. A Primer. In Handbook of Economic Evaluation of HIV Prevention Interventions. David R. Holtgrave, editor. New York: Springer Science & Business Media, 1998.

4. Satten, G., and I. Longini. "Markov Chains with Measurement Error: Estimating the True Course of a Marker of the Progression of Human Immunodeficiency Virus Disease (with Discussion)." Applied Statistics 45 (1996): 275-310.

5. Pokrovskaya, A. V., A. A. Popova, N. N. Ladnaya, and O. O. Yurin. "The Duration of the HIV Infection and the Factors Influencing It." Terapevticheskij Arhiv, no. 11 (2014): 20-23.

6. Lohse, Nicolai, A. B. Hansen, and G. Pedersen. "Survival of Persons with and without HIV Infection in Denmark, 1995–2005." Annals of Internal Medicine 146, no. 2 (2007): 87-95. doi:10.7326/0003-4819-146-2-200701160-00003.

7. Schackman, B. R., K. A. Freedberg, and M. C. Weinstein. "Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-infected Adults." Arch. Intern. Med. 162, no. 21, 2478-486.

8. Pokrovskij, V. V., O. G. Yurin, and A. V. Kravchenko. National Guidelines for Dispensary Observation and Treatment of Patients with HIV Infection. Moscow: Federal Scientific and Methodological Center for Prevention and Control of AIDS, 2015. Assessed at: http://hivrussia.metodlab.ru/files/Nac­_recom2015.pdf.

9. Babihina, K., G. Vergus, S. Golovin et al. Procurement of ARVs in 2015: Theory of Relativity. The Results of Monitoring of Procurement of ARV Drugs in the Russian Federation. St Petersburg: Treatment Preparedness Coalition, 2016.

10. Barinova, A. N. Justification of the Conceptual Model of Prevention of Socially Significant Diseases, Dangerous to Others. Comprehensive Assessment of the Effectiveness of the Prevention of At-risk Groups Exemplified by HIV Infection. St Petersburg: IOZ, St Petersburg, 2016.

11. Farnham, Paul G., David R. Holtgrave, Chaitra Gopalappa, Angela B. Hutchinson, and Stephanie L. Sansom. "Lifetime Costs and Quality-Adjusted Life Years Saved From HIV Prevention in the Test and Treat Era." JAIDS Journal of Acquired Immune Deficiency Syndromes 64, no. 2 (2013). doi:10.1097/qai.0b013e3182a5c8d4.

12. Hutchinson, Angela B., Pragna Patel, Stephanie L. Sansom et al. "Cost-Effectiveness of Pooled Nucleic Acid Amplification Testing for Acute HIV Infection after Third-Generation HIV Antibody Screening and Rapid Testing in the United States: A Comparison of Three Public Health Settings." PLoS Med PLoS Medicine 7, no. 9 (2010). doi:10.1371/journal.pmed.1000342.

13. Farnham, Paul G., Chaitra Gopalappa, Stephanie L. Sansom et al. "Updates of Lifetime Costs of Care and Quality-of-Life Estimates for HIV-Infected Persons in the United States." JAIDS Journal of Acquired Immune Deficiency Syndromes 64, no. 2 (2013): 183-89. doi:10.1097/qai.0b013e3182973966.

14. Holtgrave, David R., Richard J. Wolitski, Sherri L. Pals et al. "Cost-Utility Analysis of the Housing and Health Intervention for Homeless and Unstably Housed Persons Living with HIV." AIDS and Behavior 17, no. 5 (2012): 1626-631. doi:10.1007/s10461-012-0204-3.